Press Release

Morgan Lewis Advised Cyclerion Therapeutics in Exclusive Agreement with Akebia

June 07, 2021

BOSTON, June 7, 2021: Morgan Lewis represented Cyclerion Therapeutics Inc. in a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat, an oral soluble guanylate cyclase (sGC) stimulator.

Cyclerion is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Akebia is a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Morgan Lewis life sciences transactions partner Suzanne Filippi and associate Andrew Haupt represented Cyclerion.

For more, read Cyclerion’s announcement.